BA
CRVS icon

BlackRock Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

BlackRock Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$398K Sell
27,851
-428,266
-94% -$6.51M ﹤0.01% 2336
2016
Q3 		$7.5M Hold
456,117
– – 0.01% 976
2016
Q2 		$6.5M Buy
456,117
+371,217
+437% +$5.01M 0.01% 1009
2016
Q1 		$1.23M Buy
+84,900
New +$1.22M ﹤0.01% 1639

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Advisors's CRVS Position: Q4 2016 in Review

BlackRock Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 94% in Q4 2016, selling an estimated $6.51M and leaving 27,851 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #2336.

BlackRock Advisors first reported a position in CRVS in Q1 2016 and has held it in 4 quarters since. The position peaked at $7.5M in Q3 2016. 53 funds tracked by Wall St. Rank hold CRVS as of Q4 2016.

  • BlackRock Advisors held 27,851 shares of Corvus Pharmaceuticals worth $398K as of Q4 2016.
  • BlackRock Advisors sold 428,266 Corvus Pharmaceuticals shares in Q4 2016, an estimated $6.51M.
  • Corvus Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2336 holding.
  • BlackRock Advisors first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 4 quarters since.
  • BlackRock Advisors's Corvus Pharmaceuticals position peaked at $7.5M in Q3 2016.
  • 53 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.